Kimberly L. Blackwell, MD
Kimberly L. Blackwell, MD, is professor of medicine and assistant professor of radiation oncology at Duke University Medical Center and director of the breast cancer program at the Duke Cancer Institute, in Durham, North Carolina, where she oversees all basic and translational research programs involving breast cancer patients. She is board certified in medical oncology.
She has played a major role in two recently approved breast cancer drugs, lapatinib and T-DM1, both of which were studied in her laboratory and developed in trials in which she served as principal investigator. Because of her work on promising new therapies that target tumor cells selectively, she was named one of Time magazine’s 100 most influential people in the world in 2013.
Dr. Blackwell has clinical and research interests in the formation of blood vessels in breast cancer, breast cancer in younger women, hormonal therapy and HER2 targeted therapy for breast cancer. She maintains an active clinical practice and has served as the principal investigator or co-principal investigator in over 50 clinical trials in breast cancer. In addition, Dr. Blackwell has reviewed for several grant committees and peer-reviewed journals, including Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, and Cancer. She has been honored with many awards and is widely published in oncology journals.